Comparative Effectiveness of Continuous Glucose Monitoring Versus Blood Glucose Monitoring in Pregnancy With Diabetes: Systematic Review and Meta-analysis With Trial Sequential Analysis
- 1 September 2026
- journal article
- review article
- Published by American Diabetes Association in Diabetes Obesity and Cardiometabolic CARE
- Vol. 1 (5) , 963-973
Abstract
OBJECTIVE: The value of adding continuous glucose monitoring (CGM) to blood glucose monitoring (BGM) during pregnancy is unclear. PURPOSE: To clarify CGM's role in pregnancy using meta-analysis, Grading of Recommendations Assessment, Development and Evaluation (GRADE) ratings, harmonized neonate size definitions, and trial sequential analysis (TSA). DATA SOURCES: We performed bibliographic database and hand searches. We selected clinically relevant randomized controlled trials (RCTs) comparing CGM and BGM in pregnancy. DATA EXTRACTION: Neonate size measures were primary; additional maternal, obstetric, and neonatal outcomes data were also extracted. DATA SYNTHESIS: Seventeen RCTs (n = 2,672 participants) met inclusion criteria. Incidence of macrosomia was reduced overall (risk ratio [RR] 0.67 [95% CI 0.48, 0.94]; strength of evidence [SOE], moderate) and for gestational diabetes mellitus (GDM) (RR 0.55 [95% CI 0.35, 0.86]; SOE, high); incidence of large for gestational age was also reduced overall (RR 0.77 [95% CI 0.61, 0.98]; SOE, very low) and for GDM (RR 0.65 [95% CI 0.45, 0.96]; SOE, very low). Incidence of small for gestational age (SGA) was elevated with CGM but not statistically significant (RR 1.37 [95% CI 0.96, 1.95]; SOE, moderate). The TSA showed no neonate size outcome met the required information size (RIS) to draw firm conclusions, and no cumulative Z curve crossed the adjusted monitoring boundary. Summary statistical significance may fluctuate with the publication of new studies. CONCLUSIONS: CGM benefits mothers with preexisting diabetes and GDM and their neonates for varying outcomes, including reducing large size at birth. Our TSA found that the RIS for neonate size outcomes has not been reached. Literature should be monitored particularly for RCTs reporting SGA in GDM, which the TSA shows cannot be conclusively ruled out as a risk.Keywords
All Related Versions
This publication has 43 references indexed in Scilit:
- Flash glucose monitoring addition to self-monitoring of blood glucose and perinatal outcomes in gestational diabetes: a randomized controlled trialAmerican Journal of Obstetrics and Gynecology, 2026
- Continuous glucose monitoring versus self-monitoring of blood glucose in gestational diabetes: an updated systematic review and meta-analysis of randomized controlled trialsActa Diabetologica, 2026
- A randomized controlled trial of real-time continuous glucose monitoring (RT-CGM) for self-management of gestational diabetesAmerican Journal of Obstetrics & Gynecology MFM, 2025
- Periodic mobile application (eMOM) with self-tracking of glucose and lifestyle improves treatment of diet-controlled gestational diabetes without human guidance: a randomized controlled trialAmerican Journal of Obstetrics and Gynecology, 2024
- Flash glucose monitoring in gestational diabetes mellitus (FLAMINGO): a randomised controlled trialActa Diabetologica, 2023
- Short- and Long-Term Outcomes Associated with Large for Gestational Age Birth WeightObstetrics and Gynecology Clinics of North America, 2021
- Efficacy of flash glucose monitoring in pregnant women with poorly controlled pregestational diabetes (FlashMom): A randomized pilot studyNutrition, Metabolism and Cardiovascular Diseases, 2021
- Maternal and neonatal complications of fetal macrosomia: systematic review and meta‐analysisUltrasound in Obstetrics & Gynecology, 2019
- Continuous glucose monitoring versus self-monitoring of blood glucose in the treatment of gestational diabetes mellitusDiabetes Research and Clinical Practice, 2007
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002